Evidence map›Paper›PMID 40419103›Full record

ArticleThe American journal of medicine2025

Higher Risk of Kidney Failure Associated With Angiotensin Receptor Blockers vs ACE Inhibitors in Patients With Heart Failure.

Hans J Moore, Wen-Chih Wu, Paul A Heidenreich, Patrick Rossignol, Samir S Patel, Frederick Lu, Phillip H Lam, Amiya A Ahmed, Charles Faselis, Javed Butler and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Hans J MooreDepartment of Medicine, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, George Washington University, Washington, DC; Department of Medicine, Georgetown University, Washington, DC; Department of Medicine, Uniformed Services University, Washington, DC.
Wen-Chih WuDepartment of Medicine, Veterans Affairs Medical Center, Providence, RI; Department of Medicine, Brown University, Providence, RI.
Paul A HeidenreichDepartment of Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Department of Medicine, Stanford University, Stanford, CA.
Patrick RossignolUniversity of Lorraine, INSERM, Plurithematic Clinical Investigation Centre 1433, INSERM Unit 1116, Nancy University Hospital (CHRU Nancy) and F-CRIN INI-CRCT, Nancy, France; Medical Specialties and Nephrology Departments, Princess Grace Hospital, and Monaco Private Hemodialysis Centre, Monaco, and M-CRIN, Monaco.
Samir S PatelDepartment of Medicine, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, George Washington University, Washington, DC.
Frederick LuDepartment of Medicine, Veterans Affairs Medical Center, Providence, RI; Department of Medicine, Brown University, Providence, RI.
Phillip H LamDepartment of Medicine, Georgetown University, Washington, DC; Department of Cardiology, Medstar Washington Hospital Center, Washington, DC.
Amiya A AhmedDepartment of Medicine, Yale University, New Haven, CT; Department of Medicine, Veterans Affairs Medical Center, West Haven, CT.
Charles FaselisDepartment of Medicine, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, George Washington University, Washington, DC; Department of Medicine, Uniformed Services University, Washington, DC.
Javed ButlerBaylor Scott and White Research Institute, Dallas, TX; Department of Medicine, University of Mississippi, Jackson, MS.
Carlos E PalantDepartment of Medicine, George Washington University, Washington, DC.
Bertram PittDepartment of Medicine, University of Michigan, Ann Arbor, MI.
Matthew R WeirDepartment of Medicine, University of Maryland, Baltimore, MD.
Prakash DeedwaniaDepartment of Medicine, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, University of California, San Francisco, CA.
David AtkinsDepartment of Medicine, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, George Washington University, Washington, DC.
Venkatesh K RamanDepartment of Medicine, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, Georgetown University, Washington, DC.
Janani RangaswamiDepartment of Medicine, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, George Washington University, Washington, DC.
Jose D VargasDepartment of Medicine, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, Georgetown University, Washington, DC.
Sijian ZhangDepartment of Medicine, Veterans Affairs Medical Center, Washington, DC.
Charity J MorganDepartment of Medicine, Veterans Affairs Medical Center, Washington, DC; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL.
Helen M SheriffDepartment of Medicine, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, George Washington University, Washington, DC.
Qing Zeng-TreitlerDepartment of Medicine, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, George Washington University, Washington, DC.
Gregg C FonarowDepartment of Medicine, University of California, Los Angeles, CA.
Ali AhmedDepartment of Medicine, Veterans Affairs Medical Center, Washington, DC; Department of Medicine, George Washington University, Washington, DC; Department of Medicine, Georgetown University, Washington, DC. Electronic address: ali.ahmed@va.gov.

Funding

HSRD VA I01 HX002422HSRD VA SDR 02-237
6 · The paper itself

Abstract

backgroundRenin-angiotensin system (RAS) inhibition with high-dose (versus low-dose) angiotensin-converting inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) is associated with a lower risk of kidney failure in patients with heart failure. We examined whether this association varies between ACEIs and ARBs.

methodsFrom 300,361 Veterans with heart failure without baseline kidney failure initiated on ACEIs (n = 256,224) or ARBs (n = 44,137), we assembled a propensity score-matched cohort of 88,178 patients while remaining blinded to study outcomes. Hazard ratio (95% CI) for 5-year kidney failure in patients in the ARB group was estimated. Kidney failure was defined as receipt of kidney replacement therapy or persistent drop in baseline estimated glomerular filtration rate (eGFR) to <15 mL/min/1.73m

resultsMatched patients had mean age 71 years, ejection fraction 44%, eGFR 70 mL/min/1.73m

conclusionIn patients with heart failure, ARBs (vs. ACEIs) are associated with a higher risk of incident kidney failure. These findings need to be confirmed in future clinical trials.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsHeart FailureRenal InsufficiencyAgedFemaleGlomerular Filtration RateHumansMaleMiddle AgedPropensity ScoreAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsACE inhibitorsAngiotensin receptor blockersHeart failureKidney failure

Identifiers

PMID40419103
PMCPMC12844220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.